Results 11 to 20 of about 9,194 (267)

Bilateral neovascular glaucoma associated with Radium-223 infusions for prostate cancer [PDF]

American Journal of Ophthalmology Case Reports
Purpose: To report two cases of neovascular glaucoma associated with Radium-223 infusion. Observations: Presented are two patients with metastatic prostate cancer who developed uncontrolled intraocular pressure secondary to neovascular glaucoma requiring
Chelsea M. Viscardi, Jonathan Y. Rho, Charles R. Blake   +2 more
doaj   +2 more sources

The Tight Relationship Between the Tumoral Microenvironment and Radium-223 [PDF]

Biomedicines
Radium-223 (223Ra) was the first radioactive isotope approved for treating castration-resistant prostate cancer (CRPC) with symptomatic bone metastases without visceral metastatic disease.
Miriam Conte, Miriam Tomaciello, Maria Silvia De Feo, Viviana Frantellizzi, Francesco Marampon, Flaminia De Cristofaro, Giuseppe De Vincentis, Luca Filippi   +7 more
doaj   +2 more sources

Bone-Targeting Radionuclides in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review on Radium-223 Chloride (Alpharadin) in Combination with Other Therapies [PDF]

Diagnostics
Recent advances have broadened the range of therapeutic options for mCRPC, with several new treatments, including novel hormonal therapies (enzalutamide, abiraterone), chemotherapeutic agents (docetaxel, cabazitaxel), immunotherapies (sipuleucel-T), and ...
Ali H. D. Alshehri
doaj   +2 more sources

UK real-world data of radium-223 dichloride in metastatic prostate cancer. [PDF]

Nucl Med Commun
Randhawa M, Buchanan G, Stratton IM, Race G, Challapalli A, Bottomley D, Logue J, Sundar S, Robinson A, Mclaren DB, Stevenson R, O'Sullivan JM, Sweeney L, McGrane J, Jiang X, Mazhar D, Khoo V, McPhail N, Jones RJ, National Radium-223 Dichloride Audit Group.   +19 more
europepmc   +2 more sources

Zoledronic Acid Prevents Bone Resorption Caused by the Combination of Radium-223, Abiraterone Acetate, and Prednisone in an Intratibial Prostate Cancer Mouse Model. [PDF]

Cancers (Basel), 2023
An increased risk of non-pathological fractures in patients with prostate cancer and bone metastases has been associated with combination treatment with radium-223, abiraterone, and prednisone/prednisolone in the absence of bone-protecting agents.
Suominen MI, Knuuttila M, Sjöholm B, Wilson T, Alhoniemi E, Mumberg D, Käkönen SM, Scholz A.   +7 more
europepmc   +3 more sources

Brazilian profile of Radium-223 in metastatic prostate cancer: a multicentric, retrospective study. [PDF]

EJNMMI Rep
Souza S, Ribeiro F, Brito A, Minekawa T, Lopes F, Matedi S, Fockink R, Anjos D, Gomes G, Silva L, Camacho M, Santos A, Araújo W, Teixeira A, Martins R, Sanches A, Hanaoka N, Tavares R, Villela-Pedras F, Mourato F, Torricelli C, Alves T, Tavares M, Lima M, Moraes A, Sasse A, Almeida P, Etchebehere E.   +27 more
europepmc   +3 more sources

Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancerResearch in context

EClinicalMedicine, 2023
Summary: Background: Radium-223, a targeted alpha therapy, is approved to treat bone-dominant metastatic castration-resistant prostate cancer (mCRPC), based on significantly prolonged overall survival versus placebo and a favourable safety profile in ...
Celestia S. Higano, Daniel J. George, Neal D. Shore, Oliver Sartor, Kurt Miller, Peter S. Conti, Cora N. Sternberg, Fred Saad, Juan Pablo Sade, Joaquim Bellmunt, Matthew R. Smith, Kumari Chandrawansa, Per Sandström, Frank Verholen, Bertrand Tombal   +14 more
doaj   +1 more source

Impact of timing of radium‑223 administration on the survival of patients with bone metastatic castration‑resistant prostate cancer. [PDF]

Med Int (Lond), 2023
Makita K, Hamamoto Y, Kanzaki H, Yamashita N, Nagasaki K, Kido T, Miura N, Saika T, Hashine K.   +8 more
europepmc   +3 more sources

Radium-223 for metastatic, castration-resistant prostate cancer: A retrospective chart review study of real-world use in a tertiary hospital in Taiwan

Journal of the Formosan Medical Association, 2022
Background: Radium-223 is an alpha-emitting, bone-targeting radiopharmaceutical that confers a survival benefit in patients with confirmed bone-metastatic, castration-resistant prostate cancer with no visceral metastases.
Wei-Chun Weng, Li-Hua Huang, Neng-Chuan Tseng, Yen-Chuan Ou   +3 more
doaj   +1 more source

Radium-223 as an Additional Therapeutic Strategy in Highly Selected Patients With Metastatic Breast Cancer: A Case Report

Frontiers in Oncology, 2022
Radium-223 is commonly used in metastatic prostate cancer, targeting specifically bone metastases. The use of radium-223 remains, however, poorly evaluated in metastatic breast cancer.
Hélène Houssiau, Francois P. Duhoux, Didier François, Emmanuel Seront   +3 more
doaj   +1 more source